Study details
Enrolling now
Convalescent Plasma as a Possible Treatment for COVID-19
University of Illinois at Chicago
NCT IDNCT04442191ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 1 year
Ages
40+
Locations
1 site in IL
About this study
Researchers are testing if convalescent plasma, which contains antibodies from people who have recovered from COVID-19, can help people who are currently ill with the virus. The trial will compare this treatment to a placebo (an inactive substance) and assess its safety. It will last for 365 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Convalescent plasma
- 2.Receive Placebo
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: C-reactive Protein (CRP)
Body systems
Infectious